O	0	8	Efficacy
O	9	11	of
B-intervention	12	22	gabapentin
O	23	26	for
O	27	30	the
O	31	41	prevention
O	42	44	of
B-condition	45	55	paclitaxel
I-condition	56	63	induced
I-condition	64	74	peripheral
I-condition	75	85	neuropathy
O	85	86	:
O	87	88	A
O	89	99	randomized
O	100	107	placebo
O	108	118	controlled
O	119	127	clinical
O	128	133	trial
O	133	134	.

O	135	145	Neuropathy
O	146	148	is
O	149	150	a
O	151	155	dose
O	156	164	limiting
O	165	169	side
O	170	176	effect
O	177	179	of
O	180	187	taxanes
O	188	193	which
O	194	197	may
O	198	204	impact
O	205	208	the
O	209	216	quality
O	217	219	of
O	220	224	life
O	225	228	and
O	229	238	treatment
O	239	247	outcomes
O	247	248	.

O	249	253	This
O	254	264	randomized
O	265	272	placebo
O	272	273	-
O	273	283	controlled
O	284	290	double
O	290	291	-
O	291	298	blinded
O	299	307	clinical
O	308	313	trial
O	314	317	was
O	318	325	carried
O	326	329	out
O	330	332	to
O	333	339	assess
O	340	343	the
O	344	352	efficacy
O	353	355	of
O	356	366	gabapentin
O	367	369	in
O	370	380	preventing
O	381	393	chemotherapy
O	394	401	induced
O	402	412	neuropathy
O	412	413	.

B-eligibility	414	419	Women
I-eligibility	420	424	with
I-eligibility	425	431	breast
I-eligibility	432	438	cancer
O	439	443	were
O	444	454	randomized
O	455	459	into
O	460	463	two
O	464	470	groups
O	471	473	of
O	474	484	paclitaxel
O	485	497	chemotherapy
O	498	502	with
O	503	513	gabapentin
O	514	517	300
O	518	520	mg
O	520	521	/
O	521	526	three
O	527	532	times
O	533	534	a
O	535	538	day
O	539	545	orally
O	546	548	or
B-control	549	556	placebo
O	557	560	for
O	561	562	2
O	563	568	weeks
O	569	576	started
O	577	579	at
O	580	583	day
O	584	585	1
O	586	588	of
O	589	593	each
O	594	604	paclitaxel
O	605	610	cycle
O	610	611	.

O	612	615	Two
O	616	622	groups
O	623	627	were
O	628	636	compared
O	637	642	based
O	643	645	on
O	646	649	the
O	650	658	relative
O	659	668	frequency
O	669	671	of
O	672	682	neuropathy
O	683	686	and
O	687	693	change
O	694	696	in
O	697	702	nerve
O	703	713	conducting
O	714	722	velocity
O	723	724	(
O	724	727	NCV
O	727	728	)
O	728	729	.

B-intervention-participants	730	736	Twenty
O	737	742	women
O	743	747	were
O	748	756	assigned
O	757	759	to
O	760	764	each
O	765	770	study
O	771	774	arm
O	774	775	.

O	776	779	The
O	780	788	majority
O	789	791	of
O	792	795	the
B-outcome	796	806	neuropathy
O	807	809	in
O	810	820	gabapentin
O	821	826	group
O	827	830	was
O	831	836	grade
O	837	838	1
O	839	841	in
O	842	845	all
O	846	848	of
O	849	852	the
O	853	857	four
O	858	864	cycles
O	865	869	with
O	870	872	no
O	873	878	event
O	879	881	of
O	882	883	â‰¥
O	883	888	grade
O	889	890	3
O	891	901	neuropathy
O	902	904	in
O	905	909	this
O	910	915	group
O	915	916	.

O	917	925	Compared
O	926	928	to
O	929	932	the
O	933	940	placebo
O	940	941	,
O	942	945	the
B-outcome	946	950	rate
I-outcome	951	953	of
I-outcome	954	957	2nd
I-outcome	958	961	and
I-outcome	962	965	3rd
I-outcome	966	971	grade
I-outcome	972	982	neuropathy
O	983	986	was
O	987	1000	significantly
O	1001	1006	lower
O	1007	1009	in
O	1010	1013	the
O	1014	1024	gabapentin
O	1025	1030	group
O	1031	1032	(
O	1032	1033	P
O	1034	1035	=
O	1036	1037	0
O	1037	1038	.
O	1038	1041	000
O	1041	1042	)
O	1042	1043	.

O	1044	1047	The
B-outcome	1048	1054	change
I-outcome	1055	1057	in
I-outcome	1058	1061	NCV
O	1062	1067	after
O	1068	1072	four
O	1073	1079	cycles
O	1080	1082	of
O	1083	1093	paclitaxel
O	1094	1097	was
O	1098	1111	significantly
O	1112	1117	lower
O	1118	1120	in
O	1121	1124	the
O	1125	1135	gabapentin
O	1136	1141	group
O	1142	1150	compared
O	1151	1153	to
O	1154	1157	the
O	1158	1165	placebo
O	1166	1171	group
O	1172	1173	(
B-iv-bin-percent	1173	1175	17
I-iv-bin-percent	1175	1176	.
I-iv-bin-percent	1176	1177	7
I-iv-bin-percent	1177	1178	%
O	1179	1181	vs
B-cv-bin-percent	1182	1184	61
I-cv-bin-percent	1184	1185	.
I-cv-bin-percent	1185	1186	0
I-cv-bin-percent	1186	1187	%
B-outcome	1188	1195	decline
I-outcome	1196	1198	in
I-outcome	1199	1202	NCV
I-outcome	1203	1206	for
I-outcome	1207	1212	sural
O	1213	1216	and
B-iv-bin-percent	1217	1219	21
I-iv-bin-percent	1219	1220	.
I-iv-bin-percent	1220	1221	9
I-iv-bin-percent	1221	1222	%
O	1223	1225	vs
B-cv-bin-percent	1226	1228	62
I-cv-bin-percent	1228	1229	.
I-cv-bin-percent	1229	1230	5
I-cv-bin-percent	1230	1231	%
B-outcome	1232	1240	declines
I-outcome	1241	1243	in
I-outcome	1244	1247	NCV
I-outcome	1248	1251	for
I-outcome	1252	1260	peroneal
I-outcome	1261	1266	nerve
O	1266	1267	)
O	1267	1268	.

O	1269	1279	Gabapentin
O	1280	1285	given
O	1286	1290	with
O	1291	1301	paclitaxel
O	1302	1304	is
O	1305	1314	effective
O	1315	1317	in
O	1318	1321	the
O	1322	1332	prevention
O	1333	1335	of
O	1336	1348	intermediate
O	1349	1352	and
O	1353	1357	high
O	1358	1363	grade
O	1364	1376	neuropathies
O	1377	1381	both
O	1382	1393	objectively
O	1394	1397	and
O	1398	1410	subjectively
O	1410	1411	.
